Pancreatic Cancer Research

ResearcherMayo ClinicActive in the last 2 years

Richard David Schulick

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0001-7360-7338; OpenAlex author ID A5036412288, A5075915892. Sources: ClinicalTrials.gov.

Their work

Papers
85 (first author 5, last author 3)
Trials
1 (principal investigator on 1)
Grants
0
Labs led
1
Collaborators
220
Papers, trials and grants by year

2011: 8 papers · 2012: 8 papers · 2013: 5 papers · 2014: 1 paper · 2015: 2 papers · 2016: 2 papers · 2017: 2 papers, 1 trial · 2018: 6 papers · 2019: 3 papers · 2020: 5 papers · 2021: 8 papers · 2022: 5 papers · 2023: 4 papers · 2024: 9 papers · 2025: 6 papers · 2026: 11 papers

Papers 50 of 85

  1. Incidence and consequences of chyle leak after pancreatectomy for pancreatic cancer. Co-author DOI 10.1016/j.hpb.2025.10.004↗
  2. Staging laparoscopy to detect occult metastases in localized pancreatic cancer: global survey among nine international societies. Co-author DOI 10.1016/j.hpb.2025.12.001↗
  3. Neoadjuvant multiagent chemotherapy or upfront surgery for primary resectable pancreatic cancer - A retrospective intention-to-treat analysis. Co-author DOI 10.1016/j.hpb.2026.04.451↗
  4. Patterns of treatment and survival in borderline resectable and locally advanced pancreatic cancer. Co-author DOI 10.1016/j.pan.2025.12.007↗
  5. Response to 'Towards an individualized strategy in perioperative chemotherapy for pancreatic cancer'. Co-author DOI 10.1038/s41416-025-03294-w↗
  6. Neurogenic diarrhoea after superior mesenteric artery divestment or resection for pancreatic adenocarcinoma following preoperative chemotherapy: international … Co-author DOI 10.1093/bjsopen/zrag057↗
  7. Impact of preoperative radiotherapy on the risk of postpancreatectomy haemorrhage and major morbidity after resection of pancreatic adenocarcinoma including ar… Co-author DOI 10.1093/bjsopen/zrag058↗
  8. Portomesenteric Venous Thrombosis After Pancreatic Cancer Surgery With Venous Resection and Reconstruction: Timing, Incidence, and Risk Factors. Co-author DOI 10.1097/sla.0000000000006605↗
  9. Tangential Versus Segmental Portomesenteric Venous Resection During Pancreatoduodenectomy for Pancreatic Cancer: An International Multicenter Cohort Study on S… Co-author DOI 10.1097/sla.0000000000006638↗
  10. Neoadjuvant Therapy for Invasive Intraductal Papillary Mucinous Neoplasms: A Comparative Study With Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-025-18426-y↗
  11. ASO Visual Abstract: Neoadjuvant Therapy for Invasive Intraductal Papillary Mucinous Neoplasms: a Comparative Study with Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-025-18603-z↗
  12. Adjuvant Chemotherapy After Resection of Localized Pancreatic Adenocarcinoma Following Preoperative FOLFIRINOX. Co-author DOI 10.1001/jamaoncol.2024.5917↗
  13. Phase 1 Study of Adjuvant Allogeneic Granulocyte-Macrophage Colony-Stimulating Factor-Transduced Pancreatic Tumor Cell Vaccine, Low-Dose Cyclophosphamide, and … Co-author DOI 10.1016/j.ijrobp.2024.10.039↗
  14. Survival after neoadjuvant and induction FOLFIRINOX versus gemcitabine-nab-paclitaxel in patients with resected localised pancreatic adenocarcinoma: an interna… Co-author DOI 10.1038/s41416-025-03025-1↗
  15. Importance of increasing resection rates in pancreatic cancer treatment. Last author DOI 10.1093/bjsopen/zraf029↗
  16. Surgery for Borderline Resectable and Locally Advanced Pancreatic Cancer with Arterial Encasement after Neoadjuvant Therapy: A Single-center Experience. Co-author DOI 10.1097/sla.0000000000006690↗
  17. Personalizing Treatment for Pancreatic Ductal Adenocarcinoma: The Emerging Role of Minimal Residual Disease in Perioperative Decision-Making. Co-author DOI 10.3390/cancers18010094↗
  18. Pathological Complete Response in Patients With Resected Pancreatic Adenocarcinoma After Preoperative Chemotherapy. Co-author DOI 10.1001/jamanetworkopen.2024.17625↗
  19. Gaining a new angle on pancreas cancer: A pre-operative thrombelastographic parameter predicts recurrence and survival among patients with resected periampulla… Co-author DOI 10.1016/j.amjsurg.2024.115820↗
  20. Characteristics and prognosis of patients with pancreatic adenocarcinoma not expressing CA19-9: Analysis of the National Cancer Database. Co-author DOI 10.1016/j.pan.2024.11.011↗
  21. Neoadjuvant Chemotherapy Versus Upfront Surgery for Resectable Pancreatic Adenocarcinoma: An Updated Nationwide Study. Co-author DOI 10.1097/sla.0000000000005925↗
  22. REDISCOVER International Guidelines on the Perioperative Care of Surgical Patients With Borderline-resectable and Locally Advanced Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000006248↗
  23. Adjuvant Chemotherapy With or Without Radiotherapy for Resected Pancreatic Cancer After Multiagent Neoadjuvant Chemotherapy. Co-author DOI 10.1245/s10434-024-15157-4↗
  24. ASO Author Reflections: Is There a Role for Selective Adjuvant Radiotherapy in the Modern Era of Pancreatic Cancer Treatment? Co-author DOI 10.1245/s10434-024-15297-7↗
  25. Radiologic Occult Metastases in Pancreatic Cancer: Analysis of Risk Factors and Survival Outcomes in the Age of Contemporary Neoadjuvant Multi-agent Chemothera… Co-author DOI 10.1245/s10434-024-15443-1↗
  26. Dynamic Anthropometrics in Pancreatic Cancer: Associations Between Body Composition Changes During Neoadjuvant Therapy and Survival Outcomes After Resection. Co-author DOI 10.1245/s10434-024-15975-6↗
  27. Association of Adjuvant Chemotherapy in Patients With Resected Pancreatic Adenocarcinoma After Multiagent Neoadjuvant Chemotherapy. Co-author DOI 10.1001/jamaoncol.2022.5808↗
  28. "Conversion surgery" for locally advanced pancreatic cancer: A position paper by the study group at the joint meeting of the International Association of Pancr… Co-author DOI 10.1016/j.pan.2023.06.005↗
  29. Pulmonary metastasectomy is associated with survival after lung-only recurrence in pancreatic cancer. Co-author DOI 10.1016/j.surg.2023.05.008↗
  30. Comparison of Invasive Pancreatic Ductal Adenocarcinoma versus Intraductal Papillary Mucinous Neoplasm: A National Cancer Database Analysis. Co-author DOI 10.3390/cancers15041185↗
  31. New criteria of resectability for pancreatic cancer: A position paper by the Japanese Society of Hepato-Biliary-Pancreatic Surgery (JSHBPS). Co-author DOI 10.1002/jhbp.1049↗
  32. Comparing neoadjuvant chemotherapy with or without radiation therapy for pancreatic ductal adenocarcinoma: National Cancer Database cohort analysis. Co-author DOI 10.1093/bjs/znac002↗
  33. Author response to: Comment on: Comparing neoadjuvant chemotherapy with or without radiation therapy for pancreatic ductal adenocarcinoma: National Cancer Data… Co-author DOI 10.1093/bjs/znac340↗
  34. Prognosis Based Definition of Resectability in Pancreatic Cancer: A Road Map to New Guidelines. Co-author DOI 10.1097/sla.0000000000003859↗
  35. Targeting Treg-Expressed STAT3 Enhances NK-Mediated Surveillance of Metastasis and Improves Therapeutic Response in Pancreatic Adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-21-2767↗
  36. Response to radiotherapy in pancreatic ductal adenocarcinoma is enhanced by inhibition of myeloid-derived suppressor cells using STAT3 anti-sense oligonucleoti… Co-author DOI 10.1007/s00262-020-02701-w↗
  37. Impact of neoadjuvant chemotherapy and stereotactic body radiation therapy (SBRT) on R0 resection rate for borderline resectable and locally advanced pancreati… Co-author DOI 10.1016/j.hpb.2020.11.004↗
  38. Outcome of neoadjuvant treatment for pancreatic cancer in elderly patients: comparative, observational cohort study. Co-author DOI 10.1093/bjs/znab092↗
  39. Response to the Comment on "Prognosis-based Definition of Resectability in Pancreatic Cancer: A Road Map to New Guidelines". Co-author DOI 10.1097/sla.0000000000004275↗
  40. Induction of ADAM10 by Radiation Therapy Drives Fibrosis, Resistance, and Epithelial-to-Mesenchyal Transition in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-20-3892↗
  41. Vaccine-Induced Intratumoral Lymphoid Aggregates Correlate with Survival Following Treatment with a Neoadjuvant and Adjuvant Vaccine in Patients with Resectabl… Co-author DOI 10.1158/1078-0432.ccr-20-2974↗
  42. Landmark Series: Neoadjuvant Treatment in Borderline Resectable Pancreatic Cancer. First author DOI 10.1245/s10434-020-09535-x↗
  43. Selecting surgical candidates with locally advanced pancreatic cancer: a review for modern pancreatology. Co-author DOI 10.21037/jgo-21-119↗
  44. Understanding the immune landscape and tumor microenvironment of pancreatic cancer to improve immunotherapy. First author DOI 10.1002/mc.23179↗
  45. Pancreatic cancer treatment: better, but a long way to go. Last author DOI 10.1007/s00595-020-02028-0↗
  46. Surgical Outcomes After Pancreatic Resection of Screening-Detected Lesions in Individuals at High Risk for Developing Pancreatic Cancer. Co-author DOI 10.1007/s11605-019-04230-z↗
  47. Vascular Resections for Pancreatic Ductal Adenocarcinoma: Vascular Resections for PDAC. Co-author DOI 10.1177/1457496919900413↗
  48. Neoadjuvant Treatment in Pancreatic Cancer. Co-author DOI 10.3389/fonc.2020.00245↗
  49. It is time for a biological definition of locally advanced pancreatic cancer. First author DOI 10.1002/bjs.11249↗
  50. The metabolic time line of pancreatic cancer: Opportunities to improve early detection of adenocarcinoma. Co-author DOI 10.1016/j.amjsurg.2019.08.015↗

Trials 1

  1. CAR-T Hepatic Artery Infusions or Pancreatic Venous Infusions for CEA-Expressing Liver Metastases or Pancreas Cancer Principal investigator NCT02850536↗

Closest collaborators

The 25 strongest of 220 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Marco Del Chiaro · 34 shared papers, 2019–2026 · strength 6.63
  2. Oskar Franklin · 16 shared papers, 2024–2026 · strength 3.88
  3. Toshitaka Sugawara · 13 shared papers, 2023–2026 · strength 2.69
  4. Hiroyuki Ishida · 9 shared papers, 2025–2026 · strength 2.52
  5. Thomas F. Stoop · 10 shared papers, 2023–2026 · strength 2.32
  6. Atsushi Oba · 13 shared papers, 2020–2026 · strength 2.07
  7. Ana Gleisner · 12 shared papers, 2018–2026 · strength 1.86
  8. Robert J. Torphy · 9 shared papers, 2018–2024 · strength 1.54
  9. Christopher Lee Wolfgang · 22 shared papers, 2011–2026 · strength 1.35
  10. Wells A. Messersmith · 9 shared papers, 2018–2026 · strength 1.23
  11. Barish H. Edil · 24 shared papers, 2011–2024 · strength 1.12
  12. Sana D. Karam · 7 shared papers, 2021–2024 · strength 1.09
  13. Marc G. Besselink · 6 shared papers, 2022–2026 · strength 1.00
  14. Yuki Fujiwara · 4 shared papers, 2020–2026 · strength 0.86
  15. Andrii Khomiak · 3 shared papers, 2026 · strength 0.86
  16. Jun Ishida · 4 shared papers, 2023–2026 · strength 0.84
  17. Samuele Grandi · 4 shared papers, 2023–2026 · strength 0.84
  18. Joseph M. Herman · 20 shared papers, 2011–2025 · strength 0.79
  19. Ingmar Florin Rompen · 4 shared papers, 2026 · strength 0.76
  20. Bas Groot Koerkamp · 4 shared papers, 2026 · strength 0.76
  21. Poya Ghorbani · 4 shared papers, 2026 · strength 0.76
  22. Roeland F. de Wilde · 4 shared papers, 2026 · strength 0.76
  23. Martin D. McCarter · 8 shared papers, 2014–2024 · strength 0.76
  24. Marco Del Chiaro · 3 shared papers, 2024–2026 · strength 0.66
  25. Asif Halimi · 3 shared papers, 2026 · strength 0.66

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.